{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"ORR was defined as the proportion of participants who achieve an Investigator-determined BOR of PR or CR as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with colorectal cancer received selinexor 40 mg orally on Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\\^2; leucovorin 400 mg/m\\^2; 5- fluorouracil (5-FU) 400 mg/m\\^2 bolus then 5-FU 2400 mg/m\\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.","id":"OG000","title":"Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)"},{"description":"Participants with colorectal cancer received selinexor 80 mg orally on Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\\^2; leucovorin 400 mg/m\\^2; 5-FU 400 mg/m\\^2 bolus then 5-FU 2400 mg/m\\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.","id":"OG001","title":"Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)"}],"paramType":"NUMBER","populationDescription":"MITT population for the combination period included all participants who received at least 1 dose of selinexor in the combination therapy period.","reportingStatus":"POSTED","timeFrame":"Up to 25 months","title":"Combination Therapy (Arm C): Percentage of Participants With ORR as Assessed by RECIST 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}